Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;48(13):4495-4507.
doi: 10.1007/s00259-021-05456-3. Epub 2021 Jun 16.

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation

Evyn G Arnfield  1   2 , Paul A Thomas  3   4 , Matthew J Roberts  5   6   7 , Anita M Pelecanos  8 , Stuart C Ramsay  3   9 , Charles Y Lin  4   10 , Melissa J Latter  3   4 , Peter L Garcia  3 , David A Pattison  3   4
Affiliations

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation

Evyn G Arnfield et al. Eur J Nucl Med Mol Imaging. 2021 Dec.

Abstract

Purpose: [18F]PSMA-1007 offers advantages of low urinary tracer excretion and theoretical improved spatial resolution for imaging prostate cancer. However, non-specific bone lesions (NSBLs), defined as mild to moderate focal bone uptake without a typical morphological correlate on CT, are a common finding on [18F]PSMA-1007 PET/CT. The purpose of this study was to investigate the clinical outcomes of patients with [18F]PSMA-1007 avid NSBLs, to determine whether patients with NSBLs represent a higher risk clinical cohort, and to determine whether SUVmax can be used as a classifier of bone metastasis.

Methods: A retrospective audit of 214 men with prostate cancer was performed to investigate the clinical outcomes of [18F]PSMA-1007 avid NSBLs according to defined criteria. We also compared the serum PSA, Gleason score, and uptake time of patients with [18F]PSMA-1007 avid NSBLs to patients without [18F]PSMA-1007 avid bone lesions. Finally, we analysed an SUVmax threshold to identify bone metastases using ROC curve analysis.

Results: Ninety-four of 214 patients (43.9%) demonstrated at least one NSBL. No [18F]PSMA-1007 avid NSBLs met criteria for a likely malignant or definitely malignant lesion after a median 15.8-month follow-up interval (11.9% definitely benign, 50.3% likely benign, and 37.7% equivocal). There were no statistically significant differences in serum PSA, Gleason score, and uptake time between patients with [18F]PSMA-1007 avid NSBLs and those without [18F]PSMA-1007 avid bone lesions. All NSBLs with adequate follow-up had SUVmax ≤ 11.1. The value of the highest SUVmax distinguished between NSBLs and definite prostate cancer bone metastases, whereby an SUVmax threshold of ≥ 7.2 maximized the Youden's index.

Conclusion: [18F]PSMA-1007 avid NSBLs rarely represent prostate cancer bone metastases. When identified in the absence of definite metastatic disease elsewhere, it is appropriate to classify those with SUVmax < 7.2 as likely benign. NSBLs with SUVmax 7.2-11.1 may be classified as equivocal or metastatic, with patient clinical risk factors, scan appearance, and potential management implications used to guide interpretation.

Keywords: Bone metastases; Prostate cancer; [18F]PSMA-1007 PET.

PubMed Disclaimer

Comment in

References

    1. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet. 2020;395:1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7 . - DOI
    1. Kesch C, Kratochwil C, Mier W, Kopa K and Giesel FL. Gallium-68 or fluorine-18 for prostate cancer imaging? J Nucl Med. 2017:687-8.
    1. Dietlein F, Kobe C, Hohberg M, Zlatopolskiy BD, Krapf P, Endepols H, et al. Intraindividual comparison of 18 F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med. 2020;61:729. - DOI
    1. Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. (68)Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345–53. https://doi.org/10.1007/s00330-016-4308-4 . - DOI - PubMed
    1. Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, et al. Frusemide aids diagnostic interpretation of (68) Ga-PSMA positron emission tomography/CT in men with prostate cancer. J Med Imaging Radiat Oncol. 2017;61:739–44. https://doi.org/10.1111/1754-9485.12625 . - DOI - PubMed

LinkOut - more resources